

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners IX, LLC</u> (Last) (First) (Middle) 8755 W. HIGGINS ROAD SUITE 1025 (Street) CHICAGO IL 60631 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Beam Therapeutics Inc. [BEAM]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/10/2020		C ⁽¹⁾		4,121,520	A	(1)	4,121,520	I	See footnote ⁽²⁾
Common Stock	02/10/2020		C ⁽¹⁾		4,121,519	A	(1)	4,121,519	I	See footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			1,338,000	(1)	(1)	Common Stock	1,338,000	(1)	0	I	See footnote ⁽²⁾
Series A-1 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			1,338,000	(1)	(1)	Common Stock	1,338,000	(1)	0	I	See footnote ⁽³⁾
Series A-2 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			2,750,336	(1)	(1)	Common Stock	2,750,336	(1)	0	I	See footnote ⁽²⁾
Series A-2 Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			2,750,335	(1)	(1)	Common Stock	2,750,335	(1)	0	I	See footnote ⁽³⁾
Series B Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			33,184	(1)	(1)	Common Stock	33,184	(1)	0	I	See footnote ⁽²⁾
Series B Preferred Stock	(1)	02/10/2020		C ⁽¹⁾			33,184	(1)	(1)	Common Stock	33,184	(1)	0	I	See footnote ⁽³⁾

1. Name and Address of Reporting Person*
ARCH Venture Partners IX, LLC
 (Last) (First) (Middle)
 8755 W. HIGGINS ROAD
 SUITE 1025
 (Street)
 CHICAGO IL 60631
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ARCH Venture Partners IX, L.P.
 (Last) (First) (Middle)
 8755 W. HIGGINS ROAD

SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners IX Overage, L.P.](#)

(Last) (First) (Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund IX, L.P.](#)

(Last) (First) (Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund IX Overage, L.P.](#)

(Last) (First) (Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[CRANDELL KEITH](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS IX, LLC
8755 W. HIGGINS ROAD SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[BYBEE CLINTON](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS IX, LLC
8755 W. HIGGINS ROAD SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

Explanation of Responses:

1. Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series B Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock, Series A-2 Preferred Stock, or Series B Preferred Stock.
2. These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
3. These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be

